Your session is about to expire
← Back to Search
Retatrutide Dose Level 2 for Type 2 Diabetes
Study Summary
"This trial will compare the effectiveness and safety of retatrutide and semaglutide in people with Type 2 Diabetes who are not managing their blood sugar well with metformin alone or with
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2018 Phase 3 trial • 458 Patients • NCT03015220Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Are patients currently able to enroll in this ongoing clinical trial?
"According to the details on clinicaltrials.gov, recruitment for this investigation is presently closed. The trial was first posted on March 20, 2024 and last revised on February 8, 2024. Although this specific study is not enrolling participants currently, there are a total of 1361 other studies actively seeking eligible patients at present."
At how many different sites is the administration of this trial being managed?
"The trial is being conducted at Arcturus Healthcare, PLC in Troy, Michigan; the Internal Medicine Research Division of Troy; Medication Management in Greensboro, North carolina; and RM Pharma Specialists in Mexico City. Additionally, there are 71 more locations participating in this study."
Has the initial dosage of Retatrutide been officially endorsed by the FDA?
"The safety evaluation for Retatrutide Dose Level 1 yielded a rating of 3, as per our team at Power. This assessment is based on the trial being in Phase 3 and having substantial efficacy data along with numerous rounds validating its safety profile."
Who else is applying?
What site did they apply to?
What portion of applicants met pre-screening criteria?
Why did patients apply to this trial?
Share this study with friends
Copy Link
Messenger